Brought to you by 
Genentech, Idec develop anti-CD20 antibodies; Ocrevus, mosunetuzumab part of collaboration, glofitamab added
19 Dec 2022
Executive Summary
Genentech and Idec Pharmaceuticals (develops, sells immunotherapies) agreed to co-develop and sell humanized anti-CD20 molecules effective against a variety of B-cell disorders, including autoimmune diseases and cancer.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genentech, Idec develop anti-CD20 antibodies; Ocrevus, mosunetuzumab part of collaboration, glofitamab added
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice